Walgreens Boots Alliance (NASDAQ:WBA) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Walgreens Boots Alliance (NASDAQ:WBA) in a research note issued to investors on Friday. The brokerage issued a hold rating on the pharmacy operator’s stock.

Other equities analysts also recently issued research reports about the stock. Wolfe Research raised shares of Walgreens Boots Alliance to a “hold” rating in a research note on Monday, February 24th. Deutsche Bank Aktiengesellschaft cut Walgreens Boots Alliance from a “hold” rating to a “sell” rating and decreased their price objective for the stock from $11.00 to $9.00 in a report on Friday, February 28th. Royal Bank of Canada upped their target price on Walgreens Boots Alliance from $9.00 to $12.00 and gave the company a “sector perform” rating in a research note on Wednesday, January 15th. Bank of America raised their price target on Walgreens Boots Alliance from $7.50 to $8.50 and gave the stock an “underperform” rating in a research note on Monday, January 13th. Finally, Truist Financial dropped their price objective on shares of Walgreens Boots Alliance from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Friday, January 31st. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $10.59.

Walgreens Boots Alliance Price Performance

Shares of NASDAQ WBA opened at $10.78 on Friday. The company has a current ratio of 0.64, a quick ratio of 0.30 and a debt-to-equity ratio of 0.68. The company’s 50-day moving average price is $10.75 and its 200 day moving average price is $10.08. Walgreens Boots Alliance has a 52 week low of $8.08 and a 52 week high of $18.83. The stock has a market cap of $9.32 billion, a price-to-earnings ratio of -1.05, a PEG ratio of 1.31 and a beta of 0.67.

Walgreens Boots Alliance (NASDAQ:WBA) last issued its quarterly earnings data on Tuesday, April 8th. The pharmacy operator reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.53 by $0.10. The business had revenue of $38.59 billion during the quarter, compared to analysts’ expectations of $37.90 billion. Walgreens Boots Alliance had a negative net margin of 5.87% and a positive return on equity of 17.61%. The company’s revenue was up 4.1% on a year-over-year basis. During the same period last year, the company posted $1.20 EPS. As a group, research analysts forecast that Walgreens Boots Alliance will post 1.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. SeaCrest Wealth Management LLC raised its position in shares of Walgreens Boots Alliance by 10.1% during the 1st quarter. SeaCrest Wealth Management LLC now owns 38,136 shares of the pharmacy operator’s stock valued at $426,000 after acquiring an additional 3,504 shares in the last quarter. Curat Global LLC acquired a new stake in shares of Walgreens Boots Alliance during the first quarter worth $27,000. Sentry Investment Management LLC bought a new position in shares of Walgreens Boots Alliance in the 1st quarter worth about $27,000. Czech National Bank boosted its holdings in shares of Walgreens Boots Alliance by 5.9% in the 1st quarter. Czech National Bank now owns 164,740 shares of the pharmacy operator’s stock valued at $1,840,000 after buying an additional 9,115 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Walgreens Boots Alliance by 17.4% during the 1st quarter. Rhumbline Advisers now owns 1,518,348 shares of the pharmacy operator’s stock valued at $16,960,000 after buying an additional 224,554 shares during the last quarter. 58.59% of the stock is owned by institutional investors and hedge funds.

About Walgreens Boots Alliance

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.